http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011522022-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-84 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
| filingDate | 2009-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2011522022-A |
| titleOfInvention | Substituted quinazoline |
| abstract | The present invention relates to the discovery of substituted analogs of the selective thrombocytopenic anagrelide that reduces the likelihood of cardiovascular side effects and improves patient compliance and safety in the treatment of myeloproliferative disorders. In more detail, the present invention provides the general formula shown below: (Wherein the substituent has the meaning defined in claim 1) and relates to a specific imidazoquinazoline derivative having utility as a thrombocytopenic agent in humans. The compounds of the present invention function by inhibiting megakaryocyte formation and thus platelet formation. [Selection] Figure 1 |
| priorityDate | 2008-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 282.